Growth of Swiss biotech sector exceeds 5% in 2015 – financing at record level
The Swiss biotech industry can look back upon a successful 2015: net sales of 279 companies increased by 5.1% to 5,133 million Swiss francs ($5.4 billion).
Capital investment increased by one fourth to a record high of 907 million francs. As in previous years, a number of new companies were founded and around400 new jobs created. The future also looks promising: high-calibre innovation networks are laying the foundation for a large number of patents that will pay dividends in the next years to come.
The Swiss Biotech Report presented to the public today shows the favorable economic development of the pharmaceutical biotech sector ('red biotechnology' or 'biotech healthcare') last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze